中石化(00386.HK)称销售公司未有上市时间表不存在搁置计划
中石化(00386.HK)副总裁黄文生在中期业绩记者会上表示,集团作为控股股东於2017年批准销售公司分拆上市,销售公司於去年完成股份制改造,公司管理层会根据本身经营、管理及未来发展等择机上市,但目前未有时间表,亦不存在搁置上市的情况。
他又指,集团上半年资本开支按年增加81%至429亿元人民币,其中约45%用於上游开采及勘探,其余则用於炼油、成品油销售及化工等业务,因此不存在只投上游不投下游的说法,集团亦预料能够完成今年全年的资本开支目标。
有传国家管网公司将於今年成立并进行上市,黄文生称国家正就管网改革方案做准备,集团对管道公司上市情况不清楚,有关当局亦未就管线问题提出详细方案。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.